Immunologic Deficiency Syndromes Clinical Trial
Official title:
Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Registry for Patients Treated With Strimvelis (Previously GSK2696273) Gene Therapy: Long-Term Prospective, Non-Interventional Follow-up of Safety and Effectiveness
Adenosine deaminase (ADA) enzyme deficiency results in severe combined immunodeficiency (SCID), a fatal autosomal recessive inherited immune disorder. Strimvelis (or GSK2696273) is a gene therapy intended for patients with ADA-SCID and for whom no suitable human leukocyte antigen (HLA) matched related stem cell donor is available. This therapy aims to restore ADA function in hematopoietic cell lineages, and in doing so prevents the pathology caused by purine metabolites (i.e., impaired immune function). This registry evaluates the long term safety and effectiveness outcomes of subjects who have received Strimvelis (or GSK2696273).
This is a prospective, non-interventional follow-up registry of patients with ADA-SCID treated with Strimvelis™. The registry does not have a comparator group and the product will have been given on a single occasion prior to entering this registry. Safety and effectiveness will be assessed for a target number of 50 patients who will have received Strimvelis™ (or GSK2696273) comprising patients treated prior to marketing authorisation (i.e. clinical studies and compassionate use programs) and those treated after marketing authorisation (including within compassionate use and early access programs). The registry will close to enrolment when 50 patients have been enrolled but will not close completely until the 50th patient finishes their 15 year follow-up. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04798677 -
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
|
N/A | |
| Completed |
NCT02783482 -
Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
|
Phase 3 | |
| Completed |
NCT00598481 -
ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID
|
Phase 2 | |
| Completed |
NCT00468273 -
A Clinical Study of Intravenous Immunoglobulin
|
Phase 3 | |
| Completed |
NCT01727895 -
Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans
|
N/A | |
| Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
| Recruiting |
NCT03920735 -
Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients
|
||
| Completed |
NCT00001438 -
A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes
|
Phase 2 | |
| Terminated |
NCT00811174 -
Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases
|
Phase 3 | |
| Completed |
NCT00006131 -
Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster
|
N/A | |
| Recruiting |
NCT02735824 -
Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies
|
||
| Completed |
NCT02554630 -
Novel Mechanisms and Approaches to Treat Neonatal Sepsis
|
||
| Recruiting |
NCT03835312 -
Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DM
|
N/A | |
| Completed |
NCT00176865 -
Stem Cell Transplant for Immunologic or Histiocytic Disorders
|
Phase 2 | |
| Completed |
NCT00001646 -
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
|
Phase 3 | |
| Completed |
NCT02630082 -
Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru
|
N/A | |
| Completed |
NCT00001158 -
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
|
N/A |